Australia's Chimeric Therapeutics jumps on exclusive license agreement

Chimeric Therapeutics

21/11/2022 01:23

** Shares of Chimeric Therapeutics  CHM.AX  climb as much as
8.1% to A$0.094, their highest since Oct. 11
    ** The biotech firm enters an exclusive license agreement
with Case Western Reserve University, Ohio
    ** Says under agreement, CHM gains exclusive global rights
to the CORE-NK platform for oncology
    ** Says exclusive global license covers patent rights,
know-how, and biological materials for the CORE-NK manufacturing
process in the fields of use
    ** Volumes are 1.2x the 30-day average of 295,364 shares
    ** Stock has fallen 65.3% this year, as of last close 
 (Reporting by Echha Jain in Bengaluru)
 ((Echha.jain@thomsonreuters.com))